Neurological Disorders and Epilepsy Research

At Associazione La Nostra Famiglia in Conegliano, clinical research in nervous system diseases focuses on helping people with focal epilepsy and focal onset seizures or primary generalized tonic-clonic seizures. These studies are designed to test new treatment options and better understand how to reduce seizure frequency while supporting long-term safety and tolerability.

  • Testing new therapies for focal seizures in adults
  • Evaluating treatment effectiveness for epilepsy
  • Assessing safety and tolerability of emerging seizure treatments

This area reflects a strong commitment to improving care for adults living with seizure disorders through carefully monitored clinical trials.

Rare Neuromuscular and Genetic Conditions

Research in congenital, hereditary, and neonatal diseases and musculoskeletal diseases includes studies in Duchenne Muscular Dystrophy, Friedreich’s ataxia, and Angelman syndrome. The main goal is to evaluate whether new therapies can improve disease control, support function, and offer longer-term benefits for patients and families affected by these rare conditions.

  • Studying treatment options for Duchenne Muscular Dystrophy
  • Exploring therapies for Friedreich’s ataxia
  • Assessing new approaches for Angelman syndrome

These trials highlight a broad focus on rare diseases where better treatment options are still urgently needed.

Pediatric Neurorehabilitation and Developmental Disorders

The Neurorehabilitation department also supports studies in mental disorders and developmental conditions, including autism spectrum disorder and spastic cerebral palsy. Research here aims to improve symptoms, support daily functioning, and evaluate whether new treatments can be safely used in children and adolescents.

  • Evaluating care for irritability associated with autistic disorder
  • Testing new options for spastic cerebral palsy
  • Focusing on safety in pediatric and adolescent populations

These trials show an emphasis on pediatric rehabilitation and on therapies that may improve quality of life in complex neurodevelopmental disorders.